Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
Based on a central role of inflammation in pancreas cancer, the role of IL 1 in acute and
chronic inflammation , the inhibitory effect of IL 1 alfa and beta by anakinra and
preliminary experience with anakinra in combination with chemotherapy in metastasis (with
FOLFIRINOX) and localized disease (with gemcitabine/abraxane/cisplatin), a phase 2 study with
anakinra in combination with perioperative chemotherapy for patients with PDAC is being
proposed.